Evidence map›Paper›PMID 37544429›Full record

ArticleThe journal of allergy and clinical immunology. In practice2023

Rethinking Immunological Risk: A Retrospective Cohort Study of Severe SARS-Cov-2 Infections in Individuals With Congenital Immunodeficiencies.

Alan A Nguyen, Saddiq B Habiballah, Brenna LaBere, Megan Day-Lewis, Megan Elkins, Amer Al-Musa, Anne Chu, Jennifer Jones, Ari J Fried, Douglas McDonald and 10 more

Open access · greenAbstract read
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Alan A NguyenDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Saddiq B HabiballahDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Brenna LaBereDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Megan Day-LewisDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Megan ElkinsDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Amer Al-MusaDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Anne ChuDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Jennifer JonesDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Ari J FriedDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Douglas McDonaldDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
David P Hoytema van KonijnenburgDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Shira RockowitzResearch Computing, Information Technology, Boston Children's Hospital, Boston, Mass; The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Mass.
Piotr SlizResearch Computing, Information Technology, Boston Children's Hospital, Boston, Mass; The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Mass; Division of Molecular Medicine, Boston Children's Hospital, Boston, Massachusetts.
Hans C OettgenDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Lynda C SchneiderDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Andrew MacGinnitieDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Lisa M BartnikasDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Craig D PlattDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass.
Toshiro K OhsumiBe Biopharma, Boston, Mass.
Janet ChouDivision of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, Mass. Electronic address: Janet.Chou@childrens.harvard.edu.
Boston Children's Hospital · USHarvard University · USDana-Farber/Boston Children's Cancer and Blood Disorders Center · US

Funding

MOLECULAR BASIS OF ALLERGIC AND IMMUNOLOGIC DISEASET32AI007512 · NIAID · CHILDREN'S HOSPITAL BOSTON · PI Janet Chou, Peter A Nigrovic · 1996 to 2026
$13.1M
Mechanisms of a Novel Combined Immunodeficiency Caused by a Homozygous Mutation in COPG1R01AI139633 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI GEHA, RAIF SALIM · 2018 to 2022
$3.1M
Mechanisms of pediatric overweight and obesity underlying susceptibility to multisystem inflammatory syndrome in children (MIS-C)R01DK130465 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI CHOU, JANET · 2021 to 2023
$1.4M
Evaluating the Impact of School Nut-Free PoliciesK23AI143962 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI BARTNIKAS, LISA MARIE · 2019 to 2023
$970k
NIAID NIH HHS K23 AI143962NIAID NIH HHS R01 AI139633NIAID NIH HHS T32 AI007512NIDDK NIH HHS R01 DK130465
6 · The paper itself

Abstract

backgroundDebates on the allocation of medical resources during the coronavirus disease 2019 (COVID-19) pandemic revealed the need for a better understanding of immunological risk. Studies highlighted variable clinical outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in individuals with defects in both adaptive and innate immunity, suggesting additional contributions from other factors. Notably, none of these studies controlled for variables linked with social determinants of health.

objectiveTo determine the contributions of determinants of health to risk of hospitalization for SARS-CoV-2 infection among individuals with inborn errors of immunodeficiencies.

methodsThis is a retrospective, single-center cohort study of 166 individuals with inborn errors of immunity, aged 2 months through 69 years, who developed SARS-CoV-2 infections from March 1, 2020, through March 31, 2022. Risks of hospitalization were assessed using a multivariable logistic regression analysis.

resultsThe risk of SARS-CoV-2-related hospitalization was associated with underrepresented racial and ethnic populations (odds ratio [OR] 4.50; 95% confidence interval [95% CI] 1.57-13.4), a diagnosis of any genetically defined immunodeficiency (OR 3.32; 95% CI 1.24-9.43), obesity (OR 4.24; 95% CI 1.38-13.3), and neurological disease (OR 4.47; 95% CI 1.44-14.3). The COVID-19 vaccination was associated with reduced hospitalization risk (OR 0.52; 95% CI 0.31-0.81). Defects in T cell and innate immune function, immune-mediated organ dysfunction, and social vulnerability were not associated with increased risk of hospitalization after controlling for covariates.

conclusionsThe associations between race, ethnicity, and obesity with increased risk of hospitalization for SARS-CoV-2 infection indicate the importance of variables linked with social determinants of health as immunological risk factors for individuals with inborn errors of immunity.

Indexed as

COVID-19Primary Immunodeficiency DiseasesCohort StudiesCOVID-19 VaccinesHospitalizationHumansObesityRetrospective StudiesSARS-CoV-2COVID-19 VaccinesCOVID-19Health disparitiesInborn errors of immunityPrimary immunodeficiencySARS-CoV-2

Identifiers

PMID37544429
PMCPMC10839118
OpenAlexW4385605160

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.